Why It Matters
Avara Pharmaceuticals Inc. is entering federal lobbying to try to influence bipartisan legislation targeting domestic drug production and supply chain resilience. Congress is actively debating bills like the RAPID Reserve Act, the ABC Safe Drug Act, and the MMEDS Act of 2025—measures that would create federal contracting opportunities and substantial tax incentives for domestic manufacturers.
By hiring Vogel Group LLC, a firm with deep expertise in trade, manufacturing, and healthcare policy, Avara gains access to a sophisticated lobbying operation led by Alexander Nicholas Vogel Sr., who previously served as counsel to a Senate Majority Leader.
By the Numbers
Avara Pharmaceuticals Inc. retained Vogel Group LLC on January 2, 2025, marking its first federal lobbying engagement. The CDMO has no prior federal lobbying history or external advocacy spending on record.
Vogel Group has logged over $20 million in lobbying revenue since founding. The lobbying team consists of two experienced professionals: Alexander Nicholas Vogel Sr., who has represented major clients including AHIP and Humana Inc. on healthcare and manufacturing policy, and John W. Hesse II, who brings two decades of lobbying experience in tariff relief and federal contracting.
The Agenda
Avara Pharmaceuticals Inc. is lobbying Congress on pharmaceutical supply chain and domestic manufacturing policy, focusing specifically on "business operations in Oklahoma" and "financial services." These narrow but strategic areas suggest the company is seeking federal support for a manufacturing facility in Oklahoma through tax incentives, grants, or regulatory streamlining.
The legislative landscape presents significant opportunities. The RAPID Reserve Act would create federal contracts for domestic drug manufacturers to maintain strategic reserves. The MMEDS Act of 2025 offers substantial tax credits for pharmaceutical manufacturing in economically distressed areas. The ABC Safe Drug Act proposes 100% bonus depreciation for new pharmaceutical manufacturing property.
Broader Context
Congress is moving aggressively to reshape U.S. pharmaceutical manufacturing amid acute supply chain vulnerabilities. China controls 40 percent of imported drug ingredients, and nearly 700 drugs approved for use in the United States depend solely on Chinese-produced chemicals. Meanwhile, drug shortages hit 277 active cases.
The Contract Development and Manufacturing Organization sector is booming, with the global CDMO market projected to reach $465.24 billion by 2032. However, venture funding for biopharmaceutical companies fell 20 percent in Q1 2025, creating opportunities for federal incentives to fill the capital gap.
Between The Lines
Congressional urgency around pharmaceutical onshoring is creating a crowded legislative field. The RAPID Reserve Act and companion H.R. 3955 would create federal contracting programs for domestic drug manufacturers, while S. 1784 mandates supply chain risk assessments to identify foreign dependencies.
Recent hearings reflect bipartisan support. The House Energy and Commerce held "Made in America: Strengthening Domestic Manufacturing and Our Health Care Supply Chain," framing pharmaceutical manufacturing decline as a national security vulnerability. Members from both parties are championing onshoring, including Rep. Buddy Carter (R-GA) and Sen. Gary Peters (D-MI).
Competitive Landscape
Hikma Pharmaceuticals USA Inc., the Association for Accessible Medicines, Mallinckrodt Pharmaceuticals LLC, and CSL Behring LLC are actively lobbying on similar pharmaceutical manufacturing and supply chain issues. The landscape reflects intense bipartisan congressional focus on onshoring drug production, creating a crowded field of pharmaceutical manufacturers competing for influence over pending legislation offering tax incentives and regulatory streamlining.
The Bottom Line
Avara’s entry into federal lobbying represents a strategic bet on substantial legislative opportunities in pharmaceutical manufacturing policy. The company’s Oklahoma focus suggests interest in federal support for a manufacturing facility, capitalizing on bipartisan momentum to reduce Chinese supply chain dependence and strengthen domestic production capabilities.
Access the Legis1 platform for comprehensive political news, data, and insights.
Spot something wrong? Report an issue with this article